Roche

12 blockbusters: The surging list of $1B-plus drugs rolling out on the market this year might surprise you
Endpoints
Thu, 03/22/18 - 09:21 am
drug launches
Hemlibra
Roche
Biktarvy
Gilead Sciences
Ozempic
Novo Nordisk
Erleada
JNJ
Shingrix
GSK
Patisiran
Alnylam
Sanofi
Epidiolex
GW Pharma
Aimovig
Amgen
Novartis
lanadelumab
Shire
Elagolix
AbbVie
Steglatro
Pfizer
Merck
Sublocade
Indivior
Roche's Tecentriq triumphs in squamous lung cancer. Can it make its mark against Merck?
Fierce Pharma
Tue, 03/20/18 - 03:27 pm
Roche
Tecentriq
squamous non-small cell lung cancer
Merck
Keytruda
With Novartis and Roche gunning to carve up Eylea franchise, Regeneron has another PhIII success story to tell
Endpoints
Mon, 03/19/18 - 11:44 am
Novartis
Roche
Eylea
Regeneron
AbbVie blockbuster leads 2017 top drug sales; Roche cancer meds follow closely
S&P Global
Wed, 03/14/18 - 09:38 pm
AbbVie
Roche
Humira
Rituxan
Herceptin
Avastin
Beyond Flatiron: The Rising Power Of Oncology Clinical Data Companies
Forbes
Fri, 03/9/18 - 10:52 am
oncology
Clinical Data
Flatiron Health
Roche
Failure in pivotal PhIII brain cancer trial drags Israel’s VBL Therapeutics down
Endpoints
Thu, 03/8/18 - 09:39 am
clinical trials
VBL Therapeutics
VB-111
Roche
Avastin
glioblastoma
Roche, Ionis herald a big win in early-stage Huntington’s disease trial, demonstrate disease modifying potential
Endpoints
Thu, 03/1/18 - 11:48 pm
Roche
Ionis Pharmaceuticals
clinical trials
Huntington's disease
IONIS-HTT Rx
Pfizer, Roche and Allergan Weigh FDA Plans for Patient-Focused Drug Development Guidance
RAPS.org
Tue, 02/27/18 - 10:40 pm
Pfizer
Roche
Allergan
FDA
patients
drug development
In wake of Tecentriq bladder cancer bust and lost market share, Roche tries Tesaro combo
Fierce Pharma
Tue, 02/27/18 - 06:45 pm
Roche
Tecentriq
bladder cancer
Zejula
PARP inhibitors
Shionogi, Roche get their first approval for the next big thing in fighting the flu
Endpoints
Fri, 02/23/18 - 09:28 am
Shionogi
Roche
Flu
influenza
Xofluza
Japan
Tamiflu
The Deeply Human Core of Roche's $2.1B Tech Acquisition - And Why They Did It
Forbes
Sun, 02/18/18 - 02:54 pm
Roche
M&A
oncology
R&D
Flatiron Health
EHRs
AbbVie, Allergan, Roche could join Biogen, UCB in Acorda hunt: analyst
Fierce Pharma
Fri, 02/16/18 - 09:38 pm
AbbVie
Allergan
Roche
Biogen
UCB Pharma
Acorda Therapeutics
M&A
Roche to Acquire Cancer Software Startup Flatiron Health for $1.9B
Xconomy
Thu, 02/15/18 - 11:40 pm
Roche
software
Flatiron Health
M&A
Roche posts positive PhII results for bispecific antibody eye drug, joining Novartis in rivalry with Eylea
Endpoints
Mon, 02/12/18 - 09:49 am
Roche
bispecific antibodies
RG7716
Novartis
Eylea
Array melanoma drugs show significant survival versus Roche drug in study
Reuters
Wed, 02/7/18 - 09:58 am
Array Biopharma
melanoma
Roche
encorafenib
binimetinib
Roche hails another PhIII win on Tecentriq combo, reports promising kidney cancer data
Endpoints
Mon, 02/5/18 - 07:07 pm
Roche
Tecentriq
kidney cancer
Biopharma in charts: Key takeaways from Q4 earnings
Biopharma Dive
Mon, 02/5/18 - 12:35 pm
earnings
Merck
JNJ
AbbVie
Roche
Celgene
Eli Lilly
Roche announces slower growth in 2018 and investors lose interest in it
GoinPharma
Thu, 02/1/18 - 09:46 pm
Roche
earnings
Roche silently scraps two one-time blockbuster hopefuls as $725M Seragon deal craters
Endpoints
Thu, 02/1/18 - 09:49 am
Roche
Seragon
M&A
RG-6047
Roche scores an unusual ‘breakthrough’ at the FDA for an autism drug
Endpoints
Mon, 01/29/18 - 09:22 am
Roche
FDA
breakthrough status
autism
RG7314
balovaptan

Pages